Does Relmada Therapeutics (RLMD) Have the Potential to Rally 75.58% as Wall Street Analysts Expect?

Analysts' mean price target for Relmada Therapeutics (RLMD) implies 75.6% upside, suggesting constructive expectations for the stock. The article also notes that broad agreement in raising earnings estimates supports a positive view, although the price-target signal itself is described as not reliably effective. Overall impact is likely limited to stock-specific sentiment rather than broader market movement.

Analysis

Analysts' mean price target for Relmada Therapeutics (RLMD) implies 75.6% upside, suggesting constructive expectations for the stock. The article also notes that broad agreement in raising earnings estimates supports a positive view, although the price-target signal itself is described as not reliably effective. Overall impact is likely limited to stock-specific sentiment rather than broader market movement.